Key result
Induced pluripotent stem cell treatment improved ejection fraction and fractional shortening in animal models of heart failure.
Why the study?
Does induced pluripotent stem cell therapy improve ejection fraction and fractional shortening in animal models of heart failure?
Meta-Analysis (n=553)
Does induced pluripotent stem cell therapy improve ejection fraction and fractional shortening in animal models of heart failure?
Answers are grounded in this paper and cite their sources.
In a meta-analysis of animal models, iPSC-based therapy significantly improved heart function and reduced ventricular remodeling without increasing arrhythmia risk.
Background: Heart failure (HF) causes over 266,400 deaths annually. Despite treatment advancements, HF mortality remains high. Induced pluripotent stem cells (iPSCs) offer promising new options. This review assesses iPSC-based treatments for HF.Method: the review included studies from PubMed, ScienceDirect and Web of Science.Results: Analysis of 25 studies with 553 animals showed a baseline ejection fraction (EF) of 39.2 ± 8.9%. iPSC treatment significantly improved EF (MD = 8.6, p < 0.001) and fractional shortening (MD = 6.38, p < 0.001), and reduced ventricular remodeling without increasing arrhythmia risk.Conclusion: iPSC-based therapy improves heart function and reduces ventricular volumes in HF animal models, aligning with promising early clinical trial outcomes.
No takes yet. Share an insight, caveat, or question.
Le et al. (2024) conducted a meta-analysis in Heart failure (n=553). Induced pluripotent stem cells (iPSCs) was evaluated on Ejection fraction (EF) (MD 8.6, p=<0.001). Induced pluripotent stem cell treatment improved ejection fraction and fractional shortening in animal models of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: